Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

Boutin, Sylvie; Monteilhet, Virginie; Véron, P.; Leborgne, Christian; Benvéniste, Olivier; Montus, Marie; Masurier, Carole

doi:10.1089/hum.2009.182

Public

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

Published in Human Gene Therapy • Jan 22, 2010

Authors:

Sylvie Boutin

Virginie Monteilhet

P. Véron

Abstract

Antibodies to AAV following natural infections in humans may hamper AAV gene therapy approaches due to antibody mediated neutralization of the vector. The prevalence and characterization of the IgG subclass in 226 French subjects aged 25 to 64 years was tested. Results demonstrated substantial IgG1 ...

Subject

Adeno-associated virus

Virology

Genetic enhancement

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!